Cardiovascular disease prevention Public health guideline Published: 22 June 2010 www.nice.org.uk/guidance/ph25 © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights). Cardiovascular disease prevention (PH25) Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian. Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- Page 2 of conditions#notice-of-rights). 116 Cardiovascular disease prevention (PH25) Contents Overview ............................................................................................................................................................................. 5 Who is it for? .................................................................................................................................................................................... 5 Introduction ....................................................................................................................................................................... 6 1 Recommendations ...................................................................................................................................................... 7 Recommendations for policy: a national framework for action .................................................................................. 7 Recommendations for practice ................................................................................................................................................ 20 2 Public health need and practice .............................................................................................................................. 32 CVD in England and the UK ....................................................................................................................................................... 32 Risk factors for CVD ..................................................................................................................................................................... 33 How these risk factors cause many other illnesses .......................................................................................................... 34 Tackling the risk factors ............................................................................................................................................................... 34 Government policy ........................................................................................................................................................................ 35 3 Considerations ............................................................................................................................................................... 37 Introduction .................................................................................................................................................................................... 37 Population versus individual approach ................................................................................................................................. 38 Population-based approaches: health inequalities .......................................................................................................... 40 Population-level approaches: cost effectiveness .............................................................................................................. 41 Epidemiology .................................................................................................................................................................................. 41 Primordial prevention .................................................................................................................................................................. 43 Single risk factors ........................................................................................................................................................................... 44 Achieving change: national level .............................................................................................................................................. 48 Achieving change: the regional, community and private sectors ............................................................................... 50 Evidence ............................................................................................................................................................................................. 51 Interpreting the evidence ........................................................................................................................................................... 52 Other issues ..................................................................................................................................................................................... 53 4 Implementation ............................................................................................................................................................. 55 © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- Page 3 of conditions#notice-of-rights). 116 Cardiovascular disease prevention (PH25) 5 Recommendations for research ............................................................................................................................. 57 6 Updating the recommendations ............................................................................................................................ 58 7 Related NICE guidance ............................................................................................................................................... 59 References .......................................................................................................................................................................... 61 Appendix A: Membership of the Programme Development Group (PDG), the NICE project team and external contractors .................................................................................................................................... 69 Programme Development Group ............................................................................................................................................ 69 NICE project team ......................................................................................................................................................................... 70 External contractors ..................................................................................................................................................................... 71 Expert testimony ............................................................................................................................................................................ 72 Appendix B: Summary of the methods used to develop this guidance ....................................................... 74 Introduction ..................................................................................................................................................................................... 74 Guidance development ................................................................................................................................................................ 74 Key questions .................................................................................................................................................................................. 74 Reviewing the evidence .............................................................................................................................................................. 75 Economic analysis .......................................................................................................................................................................... 77 Fieldwork ..........................................................................................................................................................................................